Shopping Cart
Remove All
Your shopping cart is currently empty
Sibrafiban
😃Good
Catalog No. T28775Cas No. 172927-65-0
Alias RO-48-3657/001, RO-48-3657, RO 48-3657/001
Sibrafiban (RO 48-3657), an orally active, nonpeptide double-prodrug of Ro 44-3888, is a selective glycoprotein IIb/IIIa receptor antagonist that inhibits platelet aggregation [1] [2] [3].
Sibrafiban
😃Good
Catalog No. T28775Alias RO-48-3657/001, RO-48-3657, RO 48-3657/001Cas No. 172927-65-0
Sibrafiban (RO 48-3657), an orally active, nonpeptide double-prodrug of Ro 44-3888, is a selective glycoprotein IIb/IIIa receptor antagonist that inhibits platelet aggregation [1] [2] [3].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $977 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,270 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,990 | 6-8 weeks | 6-8 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Sibrafiban (RO 48-3657), an orally active, nonpeptide double-prodrug of Ro 44-3888, is a selective glycoprotein IIb/IIIa receptor antagonist that inhibits platelet aggregation [1] [2] [3]. |
| In vitro | The impact of Sibrafiban on platelet activation is evaluated through measures of P-selectin expression, fibrinogen binding, and microaggregate formation. Sibrafiban concentration-dependently inhibits both ADP and TRAP-induced fibrinogen binding and microaggregate formation, while having minimal effect on P-selectin expression. Furthermore, a reduction in Sibrafiban's site occupancy does not lead to an increase in platelet activation [3]. |
| In vivo | The activity of Ro 44-3888 on both ADP-induced platelet aggregation (17 μmol) and cutaneous bleeding duration was assessed in eight rhesus monkeys administered Sibrafiban at dosages of 0.25 mg/kg/day or 0.5 mg/kg/day through oral administration over eight days. Results demonstrated that Ro 44-3888 exhibits a dose-dependent maximal inhibition of ex vivo platelet aggregation alongside an extension of bleeding time [1]. |
| Synonyms | RO-48-3657/001, RO-48-3657, RO 48-3657/001 |
| Molecular Weight | 420.46 |
| Formula | C20H28N4O6 |
| Cas No. | 172927-65-0 |
| Smiles | C(C(NC(=O)C1=CC=C(C(=NO)N)C=C1)C)(=O)N2CCC(OCC(OCC)=O)CC2 |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Sibrafiban | purchase Sibrafiban | Sibrafiban cost | order Sibrafiban | Sibrafiban chemical structure | Sibrafiban in vivo | Sibrafiban in vitro | Sibrafiban formula | Sibrafiban molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.